Nusshag, Christian
Stütz, Alisa
Hägele, Stefan
Speer, Claudius
Kälble, Florian
Eckert, Christoph
Brenner, Thorsten
Weigand, Markus A.
Morath, Christian
Reiser, Jochen
Zeier, Martin
Krautkrämer, Ellen
Funding for this research was provided by:
Projekt DEAL
Article History
Received: 29 July 2020
Accepted: 20 October 2020
First Online: 5 November 2020
Competing interests
: Reiser J. is a co-founder and shareholder of Trisaq, a biotechnology company developing therapies for renal diseases. The authors declare no competing interests.